Genetic Technologies Ltd.

Genetic Technologies Ltd. is a globally focused life sciences company with offices in the U.S. and Australia. Its aim is to establish a significant market share in the fast-growing molecular diagnostics market, specifically in oncology. Its laboratory is one of the few facilities worldwide to be accredited by NATA (Australia), CLIA (U.S.) and ISO (Europe). The company's lead product, BREVAGen, is a first-in-class predictive risk test for sporadic breast cancer and was launched in the U.S. in July 2011.